Want to see NAUT full AI Analyst Report?
Total Valuation
Nautilus Biotechnolgy has a market cap or net worth of $233.83M. The enterprise value is $291.28M.
Market Cap$233.83M
Enterprise Value$291.28M
Share Statistics
Nautilus Biotechnolgy has 127,078,860 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding127,078,860
Owned by Insiders45.26%
Owned by Institutions34.95%
Financial Efficiency
Nautilus Biotechnolgy’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -35.74%.
Return on Equity (ROE)-0.38
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-35.74%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee0.00
Profits Per Employee-453.85K
Employee Count130
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nautilus Biotechnolgy is ―. Nautilus Biotechnolgy’s PEG ratio is 0.26.
PE Ratio―
PS Ratio0.00
PB Ratio1.57
Price to Fair Value1.57
Price to FCF-4.74
Price to Operating Cash Flow-4.67
PEG Ratio0.26
Income Statement
In the last 12 months, Nautilus Biotechnolgy had revenue of 0.00 and earned -59.00M in profits. Earnings per share was -0.47.
Revenue0.00
Gross Profit-6.46M
Operating Income-66.84M
Pretax Income-59.00M
Net Income-59.00M
EBITDA-52.54M
Earnings Per Share (EPS)-0.47
Cash Flow
In the last 12 months, operating cash flow was -49.86M and capital expenditures -1.57M, giving a free cash flow of -51.43M billion.
Operating Cash Flow-49.86M
Free Cash Flow-51.43M
Free Cash Flow per Share-0.40
Dividends & Yields
Nautilus Biotechnolgy pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.32
52-Week Price Change135.90%
50-Day Moving Average2.50
200-Day Moving Average2.15
Relative Strength Index (RSI)31.22
Average Volume (3m)394.63K
Important Dates
Nautilus Biotechnolgy upcoming earnings date is Aug 4, 2026, Before Open (Confirmed).
Last Earnings DateApr 28, 2026
Next Earnings DateAug 4, 2026
Ex-Dividend Date―
Financial Position
Nautilus Biotechnolgy as a current ratio of 13.33, with Debt / Equity ratio of 19.99%
Current Ratio13.33
Quick Ratio13.33
Debt to Market Cap0.11
Net Debt to EBITDA-0.34
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Nautilus Biotechnolgy has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Nautilus Biotechnolgy EV to EBITDA ratio is -5.02, with an EV/FCF ratio of -5.08.
EV to Sales0.00
EV to EBITDA-5.02
EV to Free Cash Flow-5.08
EV to Operating Cash Flow-5.20
Balance Sheet
Nautilus Biotechnolgy has $95.87M in cash and marketable securities with $28.87M in debt, giving a net cash position of $67.00M billion.
Cash & Marketable Securities$95.87M
Total Debt$28.87M
Net Cash$67.00M
Net Cash Per Share$0.53
Tangible Book Value Per Share$1.24
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Nautilus Biotechnolgy is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.00
Price Target Upside32.01% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast17.33%